No Data
No Data
Analysts Offer Insights on Healthcare Companies: VYNE Therapeutics (VYNE) and Lyell Immunopharma (LYEL)
Positive Phase 1 Results of VYN202 Bolster VYNE Therapeutics' Buy Rating
Express News | HC Wainwright & Co. Reiterates Buy on VYNE Therapeutics, Maintains $5.75 Price Target
VYNE Therapeutics Reports Results From Phase 1a Trial of VYN202
Express News | Vyne Therapeutics Inc - No Serious Adverse Events or Discontinuations Reported
Express News | Vyne Therapeutics Reports Positive Top-Line Phase 1a Mad Data for Vyn202, Its Novel BD2-Selective Bet Inhibitor